{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:54:55Z","timestamp":1789440895521,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2020206403"],"award-info":[{"award-number":["H2020206403"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["GZ2022014"],"award-info":[{"award-number":["GZ2022014"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jtct.2024.08.024","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T11:57:09Z","timestamp":1725364629000},"page":"1080.e1-1080.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"30","author":[{"given":"Ziwei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shupeng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-4428","authenticated-orcid":false,"given":"Fuxu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.08.024_bib0001","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtct.2024.08.024_bib0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2024.08.024_bib0003","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41423-020-00555-x","article-title":"Clinical development of CAR T cell therapy in China: 2020 update","volume":"18","author":"Wei","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0004","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3390\/cancers13071686","article-title":"Emerging therapeutic strategies to overcome drug resistance in multiple myeloma","volume":"13","author":"Davis","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jtct.2024.08.024_bib0005","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2024.08.024_bib0006","first-page":"119","article-title":"CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.jtct.2024.08.024_bib0007","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0008","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.08.024_bib0009","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101459","article-title":"Resistance against anti-CD19 and anti-BCMA CAR T cells: recent advances and coping strategies","volume":"22","author":"Atilla","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0011","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.08.024_bib0012","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0013","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.3390\/cancers13184706","article-title":"Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma","volume":"13","author":"Baertsch","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2024.08.024_bib0014","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/S2152-2650(21)02343-0","article-title":"P-216: daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed\/refractory myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol","volume":"21","author":"Shah","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2024.08.024_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241237594","article-title":"Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma","volume":"15","author":"Yuan","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0016","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary disease in multiple myeloma\u2014controversies and future directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2024.08.024_bib0018","unstructured":"mSMART 3.0: classification of active MM [DB \/OL]. [2019-09- 06]. Available at: https:\/\/www.msmart.org\/mm-treatment-guidelines. Accessed October 1, 2024."},{"key":"10.1016\/j.jtct.2024.08.024_bib0019","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.08.024_bib0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.08.024_bib0021","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2024.08.024_bib0023","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0024","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2024.08.024_bib0025","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2021-145572","article-title":"Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed\/refractory multiple myeloma","volume":"138","author":"Mailankody","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.08.024_bib0026","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2024.08.024_bib0027","doi-asserted-by":"crossref","first-page":"169","DOI":"10.20517\/cdr.2022.138","article-title":"Anti-BCMA novel therapies for multiple myeloma","volume":"6","author":"Sammartano","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.jtct.2024.08.024_bib0028","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0029","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0030","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0031","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2024.08.024_bib0032","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2018-99-119762","article-title":"Subgroup analyses of the randomized GMMG phase III multicenter trial relapse suggest survival benefit of salvage autologous transplant primarily in low risk multiple myeloma","volume":"132","author":"Baertsch","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.08.024_bib0033","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.08.024_bib0034","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","article-title":"Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE","volume":"35","author":"Goldschmidt","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.08.024_bib0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.08.024_bib0036","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.08.024_bib0037","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41409-024-02233-2","article-title":"Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma","volume":"59","author":"Mohan","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.08.024_bib0038","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","article-title":"Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.08.024_bib0039","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T01:52:59Z","timestamp":1762048379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724006250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2666636724006250"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.08.024","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}